Roflumilast Cream: Dermatitis Implications – Adelaide Hebert, MD
Roflumilast Cream Shows Promise for Infants and Toddlers with Atopic Dermatitis
Table of Contents
Atopic dermatitis (eczema) can be a relentless challenge for young children and their families. Now, new research is offering hope for a broader age range of patients who may benefit from roflumilast cream 0.05% (Zoryve), a non-steroidal treatment option. Recent findings presented at the DERM 2025 NP/PA CME Conference suggest the cream is safe for use in infants as young as 3 months old, paving the way for potential FDA approval to expand its use to this vulnerable population.
Expanding Treatment Options for Youngest Patients
Currently, roflumilast cream 0.05% is approved for the topical treatment of plaque psoriasis and atopic dermatitis in patients 12 years and older. Though,the need for safe and effective treatments for younger children with atopic dermatitis is significant. Conventional treatments often involve topical corticosteroids,which can have potential side effects with long-term use.
“We’re very excited to then go forward with data that will enrich the whole profile and capability of Zoryve in the realm of atopic dermatitis, even to the very youngest patients that really warrant and deserve therapy as well,” explained Adelaide hebert, MD, during her presentation at DERM 2025. ”The once-daily therapeutic option with a steroid-free product that has an excellent vehicle, I think, is going to be extremely rewarding for patients, parents, and, of course, the physicians who provide the care.”
INTEGUMENT-INFANT Study: Safety and Initial Findings
The positive outlook stems from the Phase 2 INTEGUMENT-INFANT study,an open-label safety study evaluating roflumilast cream 0.05% in infants aged 3 months to less than 2 years with mild-to-moderate atopic dermatitis. The study, presented as a poster at the conference, focused specifically on assessing the safety profile of the cream in this very young population.
While full efficacy data is still being analyzed, the initial safety results are encouraging. Researchers found the cream to be well-tolerated in infants and toddlers,with no unexpected safety signals identified. This is a crucial step towards possibly offering a steroid-free treatment option for these young patients.
What Does This Mean for Families?
For parents struggling to manage their child’s atopic dermatitis, the potential expansion of roflumilast cream’s approval coudl be a game-changer. The cream’s non-steroidal nature addresses concerns about the long-term effects of topical corticosteroids, offering a potentially safer alternative for prolonged use.The once-daily application also simplifies the treatment regimen, making it easier for busy parents to adhere to.Furthermore, the “excellent vehicle” mentioned by Dr. Hebert suggests a formulation that is gentle and well-accepted by sensitive infant skin.
The Path Forward: FDA Approval and Future Research
While the INTEGUMENT-INFANT study provides promising safety data, the ultimate decision regarding expanded approval rests with the FDA. Dr. Hebert emphasized, ”But of course, it’s up to the FDA, and we respect their input and feedback regarding the clinical trial.”
Researchers are continuing to gather data to further support the use of roflumilast cream in young children.This ongoing research will help to build a comprehensive understanding of the cream’s efficacy and long-term safety profile in this population.
If approved, this expanded indication would substantially broaden access to a valuable treatment option for infants and toddlers suffering from the discomfort and challenges of atopic dermatitis.
References
- Hebert A. Safety of Roflumilast Cream 0.05% in Infants and Toddlers with atopic Dermatitis, with Adelaide Hebert, MD. HCPLive. August 1,2025. [https://www.hcplive.com/view/safety-roflumilast-cream-0-05-infants-toddlers-atopic-dermatitis-adelaide-hebert-md](https://www.hcplive.com/view/safety-roflumilast-cream-0-05-infants-toddlers-atopic